Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 333 for:    DABIGATRAN

Dabigatran for Mitral Stenosis Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04045093
Recruitment Status : Not yet recruiting
First Posted : August 5, 2019
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
Dr. David Siu, The University of Hong Kong

Brief Summary:
Atrial fibrillation (AF) is the most common sustained cardiac arrythmia encountered in clinical practice and patients suffer from this are at increased risk of ischemic stroke and systemic thromboembolism due to the formation and embolism of left atrial thrombi. Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention amongst these patients with non-valvular AF at significant ischemic stroke risk, given the superior safety and comparable efficacy of NOACs over warfarin. However, warfarin therapy remains in the stroke prevention strategy for AF patients with mitral stenosis (MS) as NOACs lack of evidence for safety and efficacy amongst this group of patients. A local study is initiated to compare and evaluate the safety and efficacy among the two groups of anticoagulants - NOACs and traditional Warfarin therapy - in AF patients with underlying moderate to severe MS.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Mitral Stenosis Drug: Dabigatran etexilate Drug: Warfarin Phase 4

Detailed Description:

While the stroke risk amongst AF patients appears heterogeneous, patients with underlying valvular heart diseases particularly MS are at very high risk for stroke if left un-anticoagulated. However, this group of patients were typically excluded in randomized control trials. As a result, current international guidelines for management of AF do not recommend NOACs for stroke prevention in AF patients with underlying moderate or severe MS.

In a stark contrast to developed countries, mitral stenosis remains prevalent in many Asian countries. Together with the much higher intracranial haemorrhage risk in Asians on Warfarin, NOACs appear to be a very attractive and promising alternative. Nonetheless off-label use of NOACs in patients with MS is not uncommon in the real world practice. This study refers as a prospective, randomized, open-label trial with blinded end-point adjudication, aiming at evaluating the safety and efficacy of Dabigatran for stroke prevention in AF patients with underlying moderate or severe mitral stenosis.

Subjects enrolled in this study will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran (150mg or 110mg according to creatinine clearance level, twice daily) or Warfarin (targeting in the international normalized ratio (INR) range 2-3) in an open-label design. Primary and secondary outcomes will be assessed, including ischemic stroke, systemic embolism, haemorrhagic stroke, intracranial haemorrhage, major bleeding and death. The estimated sample size is approximately 686 participants.

The results will contribute to the stroke prevention strategy for patients with mitral stenosis and may be immediately translatable to real clinical practice. Ultimately, this study will provide the necessary evidence for establishing universal guidelines for this group of patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 686 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : September 30, 2022


Arm Intervention/treatment
Experimental: Dabigatran etexilate
Subjects randomized into this group will be prescribed with either Dabigatran 150mg or Dabigatran 110mg (twice daily) according to creatinine clearance level, twice daily) for stroke prevention.
Drug: Dabigatran etexilate
Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
Other Name: Pradaxa

Active Comparator: Warfarin
Subjects randomized into this group will be prescribed with Warfarin with dosage adjustment according to INR level (targeting to INR 2-3) for stroke prevention.
Drug: Warfarin
Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.




Primary Outcome Measures :
  1. Stroke [ Time Frame: 1 year ]
    It is defined as a neurological deficit of sudden onset that persisted for more than 24 hours and corresponded to a vascular territory that cannot be explained by other causes. It will be further classified as ischemic stroke and haemorrhagic stroke according to computerized axial tomography or magnetic resonance imaging of the brain.

  2. Systemic embolism [ Time Frame: 1 year ]
    It is defined as an acute vascular occlusion of an extremity or organ other than the brain, documented by imaging, surgery, and/or autopsy.


Secondary Outcome Measures :
  1. Ischemic stroke [ Time Frame: 1 year ]
    It is diagnosed with computerized axial tomography or magnetic resonance imaging of the brain.

  2. Haemorrhagic stroke [ Time Frame: 1 year ]
    It is diagnosed with computerized axial tomography or magnetic resonance imaging of the brain.

  3. Intracranial haemorrhage [ Time Frame: 1 year ]
    It consists of haemorrhagic stroke (intracerebral haemorrhage and cerebellar haemorrhage), subdural haemorrhage, and subarachnoid haemorrhage, and will be confirmed with computerized axial tomography or magnetic resonance imaging of the brain.

  4. Major bleeding [ Time Frame: 1 year ]
    It is defined as a drop in the haemoglobin level of at least 2g/dL, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ. Life-threatening bleeding includes fatal bleeding, symptomatic intracranial bleeding, bleeding with a haemoglobin drop of at least 5g/dL, or bleeding requiring transfusion of at least 4 units of blood or inotropic agents or requiring surgery.

  5. Death [ Time Frame: 1 year ]
    It is defined as medically certified cessation of life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with atrial fibrillation documented with standard 12-lead ECG documented atrial fibrillation on the day of screening or randomization
  • Patients with age 18 years old or above
  • Patients with moderate or severe mitral stenosis, i.e. mitral valvular area (MVA) <1.5cm2
  • Patients should be able to provide a written informed consent
  • Patients should have all 4 inclusion-criteria fulfilled to be qualified for the study

Exclusion Criteria:

  • Patients with prosthetic valve, or with active endocarditis
  • Patients with planned valvular intervention within 1 year
  • Patients with left atrial appendage occlusive device
  • Patients with planned AF ablation
  • Patients with history of intracranial, intraocular, spinal, or retroperitoneal bleeding
  • Unexplained anemia (haemoglobin level <10g/dL) or thrombocytopenia (platelet count <100x10*9/L)
  • Need for anticoagulant therapy of disorders other than atrial fibrillation
  • Patients receiving antiplatelet therapy for disorders other an atrial fibrillation
  • Uncontrolled hypertension (systolic blood pressure >180mmHg and/or diastolic blood pressure >100mmHg)
  • Estimated creatinine clearance equal to or less than 30mL/min
  • Liver dysfunction of Child Pugh stage B or C
  • Women who are pregnant or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study
  • Patients considered unreliable by the investigator or have a life expectancy less than 1 year because of concomitant disease, or has any condition, which in the opinion of the investigator, would not allow safe participation in the study (e.g. drug addiction, alcohol abuse)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04045093


Contacts
Layout table for location contacts
Contact: David Chung-Wah Siu, Professor +852-22553597 cwdsiu@hku.hk

Sponsors and Collaborators
The University of Hong Kong

Layout table for additonal information
Responsible Party: Dr. David Siu, Clinical Professor, The University of Hong Kong
ClinicalTrials.gov Identifier: NCT04045093     History of Changes
Other Study ID Numbers: NOAC Dabi MSAF protocol_v.1
First Posted: August 5, 2019    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dabigatran
Atrial Fibrillation
Mitral Valve Stenosis
Constriction, Pathologic
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Pathological Conditions, Anatomical
Heart Valve Diseases
Warfarin
Anticoagulants
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action